» Drug, Devices, and Supplements

» Physician Accountability

» Consumer Product Safety

» Worker Safety

» Health Care Delivery

» Auto and Truck Safety

» Global Access to Medicines

» Infant Formula Marketing


More information on nevirapine (Viramune)

Letter in the Lancet Detailing Unethical Nevirapine (Viramune) Trials

This letter, by Health Research Group Deputy Director Peter Lurie, M.D., MPH and Director Sidney Wolfe, M.D., appeared in the Lancet on November 20, 1999.

Sir--Although Laura Guay and colleagues' (Sept 4, p 795) [1] study on the effectiveness of nevirapine in reducing perinatal HIV-1 transmission offers hope for reducing the enormous global toll of HIV-1 infection, their work remains deeply unethical. For 14 months after an antepartum and intrapartum regimen of zidovudine was shown in Thailand to reduce HIV-1 transmission by 51%, [2] Guay and colleagues continued to enrol participants without providing antepartum antiretroviral drugs. This practice continued for 6 months after WHO had recommended antepartum and intrapartum zidovudine therapy in less developed countries "where adequate infrastructure is in place", [3] a condition certainly met in this study. Because the mothers were enrolled as early as 32 weeks' gestation, there was ample opportunity to provide this life-saving medication.

[1] Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354: 795-802.

[2] CDC. Administration of zidovudine during late pregnancy and delivery to prevent perinatal HIV transmission: Thailand 1996-1998. MMWR Morb Mortal Wkly Rep 1998; 47: 151-54. [PubMed]

[3] WHO. Recommendations on the safe and effective use of short-course ZDV for prevention of mother-to-child transmission of HIV. Wkly Epidemiol Rec 1998; 73: 313-20. [PubMed]

Copyright © 2016 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.

Public Citizen, Inc. and Public Citizen Foundation


Together, two separate corporate entities called Public Citizen, Inc. and Public Citizen Foundation, Inc., form Public Citizen. Both entities are part of the same overall organization, and this Web site refers to the two organizations collectively as Public Citizen.

Although the work of the two components overlaps, some activities are done by one component and not the other. The primary distinction is with respect to lobbying activity. Public Citizen, Inc., an IRS § 501(c)(4) entity, lobbies Congress to advance Public Citizen’s mission of protecting public health and safety, advancing government transparency, and urging corporate accountability. Public Citizen Foundation, however, is an IRS § 501(c)(3) organization. Accordingly, its ability to engage in lobbying is limited by federal law, but it may receive donations that are tax-deductible by the contributor. Public Citizen Inc. does most of the lobbying activity discussed on the Public Citizen Web site. Public Citizen Foundation performs most of the litigation and education activities discussed on the Web site.

You may make a contribution to Public Citizen, Inc., Public Citizen Foundation, or both. Contributions to both organizations are used to support our public interest work. However, each Public Citizen component will use only the funds contributed directly to it to carry out the activities it conducts as part of Public Citizen’s mission. Only gifts to the Foundation are tax-deductible. Individuals who want to join Public Citizen should make a contribution to Public Citizen, Inc., which will not be tax deductible.


To become a member of Public Citizen, click here.
To become a member and make an additional tax-deductible donation to Public Citizen Foundation, click here.